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Cancer patients are at high risk of developing venous 
thromboembolism (VTE), including deep venous thrombosis 
and pulmonary embolism.  
Indeed, in cancer patients VTE represents the second cause 
of death after the tumor itself, and significantly worsens their 
morbidity and the quality of life. 
It is now well established that while the presence of a tumor 
predisposes the onset of VTE in the host, the activation of 
the hemostatic system in cancer may have a role not only in 
thrombosis but also in tumor growth and dissemination.  
The effort of the current research aims to find valuable tools 
able to break down this mutual, vicious relationship. 
In this respect, heparins, particularly the low molecular 
weight (LMWH) subcategory, are good candidates in that not 
only they are the drug of choice for the prophylaxis and 
treatment of VTE in a wide spectrum of pathological settings, 
including cancer, but they also appear to be endowed with 
direct and indirect anti-tumor features. 
This has led to the development of a number of prospective 
randomized clinical trials to test LMWH to improve cancer 
survival as a primary end-point in cancer patients. Although 
the results are controversial, the interest in this research area 
remains high. Given the potential benefit of increased 
survival in oftentimes still fatal disease, any benefit, even 
small effects, may be clinically relevant. Therefore, it makes 
sense to dig deeper into the biology of cancer cells and to 
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better establish the effects of different types of heparins, on 
growth and proliferation of tumor cells.  
We choose to study the impact of heparins on the vascular 
endothelium, this because endothelial cells play multiple 
roles in several patho-physiological processes, including 
hemostatic activation and cancer progression, so they 
appear an ideal target when you aim to impair the 
cancer/thrombosis association. 
We could demonstrate that heparins may prevent the pro-
thrombotic switch of the endothelial cells when exposed to 
tumor-derived products, as well as standard cytokines. This 
is relevant because the inhibition of fibrin formation has been 
considered a possible tool against the progression of 
malignant disease.  
Endothelial cells take also part in tumor-driven angiogenesis. 
We could observe that heparins are able to impair the tumor-
induced formation of capillary-like tubules (a key step in the 
neo-angiogenesis process) by endothelial cells in the well-
known matrigel-based model. By counteracting the formation 
of new blood vessels, one could limit the tumor growth. 
Then, we showed that heparins are able to counteract the 
direct adhesion of tumor cells to the vascular endothelium 
monolayer, by employing leukemic cells (but data are 
ongoing also with cells from solid tumor). This has important 
implications in that this effect may prevent tumor 
dissemination. We also showed that heparins counteract the 
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migration of cells from pancreatic cancer, a very aggressive 
subtype of cancer. 
It has to be noted that we employed only cells of human 
origin, with regard to both endothelium and tumor. In 
particular, we used in all studies endothelial cells of the 
microcirculation, the most involved type in the pathological 
conditions, while the majority of published studies with the 
vascular endothelium have utilized cells from the 
macrocirculation. 
Moreover, in our studies, we used not only the classical 
unfractionated heparin (UFH) and various types of LMWH, 
but also one representative of the very new ultra-low 
molecular weight heparin (ULMWH) subclass, i.e. RO-14. 
These newest heparins are characterized by a lower mean 
MW, and a more defined composition of polysaccharidic 
chain content. They are also characterized with a high anti-
FXa activity and only residual anti-FIIa activity, thus the ratio 
anti-FXa/anti-FIIa is much greater compared to classical 
LMWH [1], that means that they should be endowed with a 
better efficacy/risk ratio compared to LWMH. Some ultra-
LMWH are in clinical development [1-2]. However, little is 
known about their anti-cancer effects. Indeed, we first 
describe here that one of these ultra-LMWH i.e. RO-14 
possess an anti-angiogenic activity similar to those shown by 
LMWH [3]. RO-14 also possesses a direct inhibitory effect on 
the migration of the pancreatic cancer cells.  
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With all the limitations coming from being in vitro studies, 
taken together these data further contribute to support the 
evidence of a possible in vivo anti-tumor effect of LMWH. 
They also provide ground for future extensive studies, both in 
animal models and in clinical trials, about a possible role for 
LMWH and ULMWH in the cancer/thrombosis setting. 
In summary, the potential therapeutic benefit of heparin 
derivatives for patients with malignant disease, is still out of 
reach. This does not mean that the promising findings from in 
vitro and animal studies could not translate into effective 
therapies. The use of specific fractions, such as non-
anticoagulant heparins with reduced bleeding potential, and 
the application of better experimental models of disease, 
should be able to advance our knowledge. This gain in 
knowledge should translate into feasible focused clinical 
trials in highly selected patients with cancer, as to obtain 
proof of principle data on efficacy and mechanisms of action. 
The use of biomarkers, both for cancer cell death, as well as 
for vascular damage, hypercoagulability and other markers of 
vascular disease related to cancer, should help to explore 
the underlying mechanisms further.   
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